RRD International is now RRD Biopharma Development

February 29, 2024 12:00 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

RRD Biopharma Development is the dynamic new brand of RRD International. Launched to reflect the company's unique approach to drug development through its successful Product Development Team model.

ROCKVILLE, Md., Feb. 28, 2024 /PRNewswire/ -- RRD International has announced today that it launched its new brand RRD Biopharma Development reflecting its unique offering of delivering strategy-driven product development services to biopharmaceutical companies and investors.

The rebrand includes a new updated website showcasing its innovative Product Development Team (PDT) Model. The PDT model enables biopharma companies with limited infrastructure to navigate the challenges of drug development efficiently and effectively resulting in more predictable product development outcomes.

RRD's rapid start, high caliber team partner with companies globally applying their exceptional experience to accelerate drug development and reduce risk. Investing in the asset's success, they improve value and drive patient benefits.

The company, founded in 2002, is part of Uniphar Group, a Dublin, Ireland based international diversified healthcare services company. RRD's asset-centric development approach has helped create >$3.0 billion in value for its partners over the last 21 years.

Commenting on the rebrand, Scott Tarrant, CEO of RRD Biopharma Development said: "Our unique approach uses insights and experience to strategize, optimize, and execute biopharmaceutical development, maximizing asset value and accelerating patient access to new medicines.

"Our new, dynamic brand more accurately reflects and places emphasis on our development offering and the value that we deliver every day to our partners.

"The improved branding better communicates who we are and what we do which ultimately supports our growth and makes us a recognized development partner in the market," concluded Tarrant.

About RRD Biopharma Development

RRD Biopharma Development is a product development company that provides integrated, expert-level strategic, regulatory, and operational support to biopharmaceutical companies and investors. The Company's unique Product Development Team (PDT) model provides an effective, asset-centric alternative to traditional industry practices. While comprehensive in value, structure, and function – encompassing all aspects of a development program – the PDT model is also highly resource efficient with an intense focus on minimizing cost, time, and risk to achieve significant value inflections whether that be human proof-of-concept (hPOC) or through marketing approval. Since 2002, RRD has worked with more than 200 orgainizations across all major classes and therapeutic areas. For more information, visit rrdbiodev.com.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.